MX2019007892A - Compuestos inhibidores de metaloenzimas. - Google Patents

Compuestos inhibidores de metaloenzimas.

Info

Publication number
MX2019007892A
MX2019007892A MX2019007892A MX2019007892A MX2019007892A MX 2019007892 A MX2019007892 A MX 2019007892A MX 2019007892 A MX2019007892 A MX 2019007892A MX 2019007892 A MX2019007892 A MX 2019007892A MX 2019007892 A MX2019007892 A MX 2019007892A
Authority
MX
Mexico
Prior art keywords
inhibitor compounds
metalloenzyme inhibitor
metalloenzyme
compounds
metalloenzymes
Prior art date
Application number
MX2019007892A
Other languages
English (en)
Spanish (es)
Inventor
sparks Steven
m yates Christopher
R Shaver Sammy
J Hoekstra William
Original Assignee
Selenity Therapeutics Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selenity Therapeutics Bermuda Ltd filed Critical Selenity Therapeutics Bermuda Ltd
Publication of MX2019007892A publication Critical patent/MX2019007892A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2019007892A 2016-12-29 2017-12-22 Compuestos inhibidores de metaloenzimas. MX2019007892A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662440181P 2016-12-29 2016-12-29
PCT/US2017/068190 WO2018125800A2 (en) 2016-12-29 2017-12-22 Metalloenzyme inhibitor compounds

Publications (1)

Publication Number Publication Date
MX2019007892A true MX2019007892A (es) 2020-02-05

Family

ID=62709109

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019007892A MX2019007892A (es) 2016-12-29 2017-12-22 Compuestos inhibidores de metaloenzimas.
MX2022012386A MX2022012386A (es) 2016-12-29 2019-06-28 Compuestos inhibidores de metaloenzimas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022012386A MX2022012386A (es) 2016-12-29 2019-06-28 Compuestos inhibidores de metaloenzimas.

Country Status (14)

Country Link
US (4) US10085984B2 (https=)
EP (2) EP3562487B1 (https=)
JP (2) JP7227157B2 (https=)
KR (1) KR102690885B1 (https=)
CN (2) CN110691598A (https=)
AU (2) AU2017387033B2 (https=)
CA (1) CA3055292A1 (https=)
DK (1) DK3562487T3 (https=)
ES (1) ES2967119T3 (https=)
FI (1) FI3562487T3 (https=)
MX (2) MX2019007892A (https=)
RU (1) RU2764666C2 (https=)
TW (1) TWI786078B (https=)
WO (1) WO2018125800A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2774267T3 (es) * 2012-01-20 2020-07-20 Mycovia Pharmaceuticals Inc Compuestos inhibidores de metaloenzimas
FI3562487T3 (fi) 2016-12-29 2023-12-14 Ji Xing Pharmaceuticals Hong Kong Ltd Metalloentsyymi-inhibiittoriyhdisteitä
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
CA3126224A1 (en) * 2019-01-08 2020-07-16 Corxel Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
GB201901757D0 (en) 2019-02-08 2019-03-27 Syngenta Crop Protection Ag Herbicidal compounds
CN115803317B (zh) 2020-05-19 2025-07-15 拜耳作物科学股份公司 作为杀真菌化合物的氮杂双环(硫代)酰胺
WO2021249995A1 (en) 2020-06-10 2021-12-16 Bayer Aktiengesellschaft Azabicyclyl-substituted heterocycles as fungicides
AT524288B1 (de) * 2020-09-16 2024-05-15 Gatan Inc Computergestütztes Verfahren zur Bestimmung eines Elementanteiles eines Bestimmungselementes kleiner Ordnungszahl, insbesondere eines Li-Anteiles, und Vorrichtung zur Datenverarbeitung hierzu
WO2025157275A1 (zh) * 2024-01-26 2025-07-31 箕星药业香港有限公司 金属酶抑制剂化合物的固体形式
CN120463643B (zh) * 2025-05-27 2025-11-28 咸阳职业技术学院 一种2-环丙基胺基-3-硝基-6-氯吡啶的合成方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2939916A1 (de) 1979-10-02 1981-04-23 Hoechst Ag, 6000 Frankfurt Quaternierte, verbrueckte benzimidazolyl-benzimidazole, verfahren zu deren herstellung und deren verwendung
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
EP0431519B1 (en) 1989-12-04 1994-06-15 G.D. Searle & Co. System for transdermal albuterol administration
US5106863A (en) 1990-03-26 1992-04-21 Ortho Pharmaceutical Corporation Substituted imidazole and pyridine derivatives
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
DE69228827T2 (de) 1991-12-18 1999-10-21 Minnesota Mining And Mfg. Co., Saint Paul Mehrschichtige sperrstrukturen
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
AU5886500A (en) 1999-06-23 2001-01-09 Sepracor, Inc. Indolyl-benzimidazole antibacterials, and methods of use thereof
JP5039268B2 (ja) 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
AU2003235741B8 (en) * 2002-01-07 2009-01-15 Eisai R&D Management Co., Ltd. Deazapurines and uses thereof
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1604988A1 (en) * 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
PL1861387T3 (pl) 2005-01-28 2014-08-29 Dae Woong Pharma Pochodne benzoimidazolu i ich kompozycje farmaceutyczne
AR055669A1 (es) * 2005-10-03 2007-08-29 Astrazeneca Ab Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
EP1960382A1 (en) 2005-11-03 2008-08-27 ChemBridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
US20080027044A1 (en) 2006-06-13 2008-01-31 Kim Lewis Prodrug antibiotic screens
EP1878724A1 (en) 2006-07-15 2008-01-16 sanofi-aventis A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles
MX2009011208A (es) 2007-04-19 2009-10-30 Novartis Ag Derivados de acido nicotinico como moduladores del receptor de glutamato metabotropico-5.
US7737175B2 (en) 2007-06-01 2010-06-15 Duke University Methods and compositions for regulating HDAC4 activity
WO2009000413A1 (en) 2007-06-26 2008-12-31 Sanofi-Aventis A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
JP5142836B2 (ja) 2007-07-02 2013-02-13 オセ−テクノロジーズ ビーブイ 走査画像要素位置合わせ方法
US20100216796A1 (en) 2007-10-04 2010-08-26 Solomon Kattar N-hydroxy-naphthalene dicarboxamide and n-hydroxy-biphenyl-dicarboxamide compounds as histone deacetylase inhibitors
EP2732819B1 (en) 2008-02-07 2019-10-16 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh-1 expression
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
GB0821994D0 (en) 2008-12-02 2009-01-07 Ge Healthcare Ltd In viva imaging method
HRP20140371T1 (hr) 2009-05-15 2014-05-23 Novartis Ag Arilpiridini kao inhibitori sinteze aldosterona
US8519134B2 (en) 2009-11-17 2013-08-27 Novartis Ag Aryl-pyridine derivatives as aldosterone synthase inhibitors
AU2011242562B2 (en) * 2010-04-24 2016-10-13 Mycovia Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US9382226B2 (en) * 2010-07-21 2016-07-05 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
US20130227717A1 (en) 2010-10-08 2013-08-29 Life Sciences Research Partners Vzw Hdac inhibitors to treat charcot-marie-tooth disease
EP3483147A1 (en) * 2010-11-13 2019-05-15 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US8815854B2 (en) * 2011-06-24 2014-08-26 Arqule, Inc. Substituted imidazopyridinyl compounds
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013134472A1 (en) * 2012-03-08 2013-09-12 Medtronic Ardian Luxembourg S.A.R.L. Renal neuromodulation methods and systems for treatment of hyperaldosteronism
CN103626783B (zh) * 2012-08-22 2016-06-08 中国科学院上海药物研究所 双环稠杂环化合物及其用途和药物组合物
US10022357B2 (en) 2013-04-29 2018-07-17 The General Hospital Corporation Amyloid precursor protein MRNA blockers for treating Down syndrome and Alzheimer's disease
MY176401A (en) * 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
WO2015188369A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
AP2017009829A0 (en) * 2014-10-15 2017-03-31 Boehringer Ingelheim Int Aldosterone synthase inhibitors
ES2959782T3 (es) 2016-12-20 2024-02-28 Fmc Corp Oxadiazoles fungicidas
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
FI3562487T3 (fi) 2016-12-29 2023-12-14 Ji Xing Pharmaceuticals Hong Kong Ltd Metalloentsyymi-inhibiittoriyhdisteitä
CA3126224A1 (en) 2019-01-08 2020-07-16 Corxel Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds

Also Published As

Publication number Publication date
RU2764666C2 (ru) 2022-01-19
AU2017387033B2 (en) 2024-02-01
EP4311577A3 (en) 2024-04-17
EP3562487B1 (en) 2023-11-29
AU2017387033A1 (en) 2019-08-15
CA3055292A1 (en) 2018-07-05
BR112019013478A2 (pt) 2020-01-07
US12458642B2 (en) 2025-11-04
JP2023071692A (ja) 2023-05-23
AU2024202860A1 (en) 2024-05-23
US10085984B2 (en) 2018-10-02
US20190008861A1 (en) 2019-01-10
JP7611278B2 (ja) 2025-01-09
FI3562487T3 (fi) 2023-12-14
TW201831465A (zh) 2018-09-01
CN110691598A (zh) 2020-01-14
EP3562487A2 (en) 2019-11-06
JP2020510693A (ja) 2020-04-09
DK3562487T3 (da) 2024-01-02
TWI786078B (zh) 2022-12-11
US11040034B2 (en) 2021-06-22
EP4311577A2 (en) 2024-01-31
RU2019123854A (ru) 2021-02-01
WO2018125800A2 (en) 2018-07-05
KR20190129034A (ko) 2019-11-19
US20260097034A1 (en) 2026-04-09
WO2018125800A3 (en) 2018-08-16
CN120987917B (zh) 2026-03-20
US20180185362A1 (en) 2018-07-05
CN120987917A (zh) 2025-11-21
RU2019123854A3 (https=) 2021-05-12
EP3562487A4 (en) 2020-08-26
MX2022012386A (es) 2022-11-30
JP7227157B2 (ja) 2023-02-21
ES2967119T3 (es) 2024-04-26
US20210322409A1 (en) 2021-10-21
KR102690885B1 (ko) 2024-08-02

Similar Documents

Publication Publication Date Title
MX2019007892A (es) Compuestos inhibidores de metaloenzimas.
ECSP22051489A (es) Compuestos inhibidores de metaloenzimas
MX376201B (es) Compuestos inhibidores de metaloenzima.
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
CY1120246T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
EA201790998A1 (ru) Иммуннорегуляторные агенты
PH12013502622A1 (en) Metalloenzyme inhibitor compounds
PH12013502624A1 (en) Metalloenzyme inhibitor compounds
BR112017006664A2 (pt) terapias de combinação
UY36080A (es) Compuestos inhibidores de metaloenzima como fungicidas.
IN2014DN06792A (https=)
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
EA201790806A1 (ru) Иммунорегулирующие средства
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
MX377273B (es) Ciclopropilamina como inhibidor de la desmetilasa 1 específica de lisinas (lsd1).
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
PE20151594A1 (es) Inhibidores de indolamina 2-3 dioxigenasa
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201591278A1 (ru) Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
EA201591705A1 (ru) Композиции и способы для диагностики и лечения рака печени
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.